New role for a driver of metastatic cancers

April 02, 2019

LA JOLLA--(April 2, 2019) Metastatic ovarian, prostate and breast cancers are notoriously difficult to treat and often deadly. Now, Salk Institute researchers have revealed a new role for the CDK12 protein. The findings were published in the print version of Genes & Development on April 1, 2019.

"Approximately 3-5 percent of prostate, ovarian, and breast cancers contain mutations in the CDK12 gene, and recent studies have shown that this subset is uniquely responsive to immunotherapy drugs, whereas the majority of these cancers do not respond," says Salk Professor Katherine Jones, senior author of the paper. "This suggests, for the majority of these cancers that lack a CDK12 mutation, chemical inhibitors of CDK12 could be used to make the cancer more easily killed by chemotherapy drugs, and potentially more sensitive to immunotherapy treatments as well." The results suggest it could be a drug target for many cancers that have spread throughout the body.

By analyzing the role of CDK12 in protecting the cells from chemotherapy, the group discovered a new group of genes that are controlled by CDK12, including many genes that are regulated by another protein called mTORC1, which controls cancer cell metabolism. And although CDK12 is predominantly located in the nucleus of the cell, it works with mTORC1 to control the process of translation--an important step in creating a new protein within the cell.

"CDK12 is a recently identified gene that controls the expression of genes required for DNA repair, but its detailed mechanism and function are just beginning to be explored," says first author Seung Choi, a former staff scientist and a current Salk research collaborator. "Therefore, if CDK12 is inhibited, the cell cannot repair DNA efficiently, and the cells are more prone to dying in response to chemotherapy. We wanted to understand how CDK12 might be involved in cancer in order to advance cancer treatment options."

In a collaboration with the lab of Salk Professor Alan Saghatelian, the team was able to identify specific genes that were regulated by CDK12 at the level of translation. Several hundred genes were found to be controlled by CDK12 in this new way, many of which are tied to cancer cell growth.

To the surprise of the researchers, many of the other newly identified CDK12-regulated genes were critical for cell division (mitosis). Microscopy imaging studies by Seunjae Kim, a postdoctoral fellow at Salk, revealed that CDK12 helped the chromosomes condense and then separate to become two distinct cells. This role for CDK12 in the expression of a whole network of genes necessary for mitosis was entirely unknown.

"We've discovered a new translation pathway that nobody knew existed, which is used by a lot of the factors that are involved in cell division--specifically, separating the chromosomes," says Jones, who holds the Edwin K. Hunter Chair in the Regulatory Biology Laboratory. "This new information about the role of CDK12 helps us understand how cancer cells are disorganized, and also how chemical inhibitors of CDK12 could help kill cancer cells. The findings suggest that targeted inhibitors to CDK12 might also block parts of the mTOR pathway, and synergize with mTOR inhibitors or mitotic inhibitors that are important components of current therapies."

The scientists are now studying how CDK12 is inhibited in normal cells, which could suggest new approaches to blocking CDK12 activity in metastatic cancer cells therapy.
Other authors included Thomas F. Martinez, Seongjae Kim, Cynthia Donaldson, Maxim N. Shokhirev and Alan Saghatelian.

The work was funded by The Jean Hahn Hardy Fellowship, the Salk Alumni Fellowship, the Pioneer Fund Scholar Awards, the National Institutes of Health (NRSA F32GM123685, 5R01HD092215 and R01CA125535).

About the Salk Institute for Biological Studies:

Every cure has a starting point. The Salk Institute embodies Jonas Salk's mission to dare to make dreams into reality. Its internationally renowned and award-winning scientists explore the very foundations of life, seeking new understandings in neuroscience, genetics, immunology, plant biology and more. The Institute is an independent nonprofit organization and architectural landmark: small by choice, intimate by nature and fearless in the face of any challenge. Be it cancer or Alzheimer's, aging or diabetes, Salk is where cures begin. Learn more at:

Salk Institute

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to